Seung Il Kim, Jee Ye Kim

Liquid Biopsy for Cancer

Current Status and Future Challenges

• Gebundenes Buch

Produktbeschreibung

Individual tumour molecular profiling and tacking dynamic evolution by treatment related selective pressure are crucial for clinical oncology. However, current tissue biopsy cannot represent spatial and temporal tumour heterogeneity due to sampling bias.

Liquid biopsy is an alternative way of tissue biopsy since it can represent comprehensive molecular signature from multiple distinct lesions and real time tracking is feasible by repeated longitudinal assay during course of treatment.

This book describes current knowledge regarding pre-analytical issues including standardization of blood preparation, analytical variability, clinical application and regulatory agency approval issue, etc. Regarding targets in circulation, it focuses on circulating tumour cells (CTCs), circulating nucleic acid (ctDNA, cell free RNAs), extracellular vesicles, tumour educated platelets, and others (proteins, metabolites).
The book will be a rich source of information and instruction for oncologists and offers stimulating ideas on prospects for further progress in this field.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Springer / Springer Nature Singapore / Springer, Berlin
• Artikelnr. des Verlages: 978-981-99-4417-0
• 2024
• Seitenzahl: 150
• Erscheinungstermin: 12. April 2025
• Englisch
• Abmessung: 254mm x 178mm
• ISBN-13: 9789819944170
• ISBN-10: 9819944171
• Artikelnr.: 68171330

Autorenporträt

Seung Il Kim, MD, PhD. Professor., Department of Medical Oncology, Yonsei University College of Medicine Jee Ye Kim, MD, PhD. Professor., Department of Medical Oncology, Yonsei University College of Medicine

Inhaltsangabe

1. Introduction.- 2. Technical issue for implementation of liquid biopsy.- 3. Targets in circulation.- A. circulating tumour cells (CTCs).- B. circulating nucleic acid (ctDNA, cell free RNAs).- C. extracellular vesicles.- D. tumour educated platelets.- E. others (proteins, metabolites).- 4. Liquid biopsy as cancer screening: early cancer detection in general population.- 5. Liquid biopsy for patients with cancer.- A. treatment response monitoring.- B. MRD monitoring: early detection of recurrence.- C. Resistance mechanism tracking.- 6. Future perspectives.